Welcome to our dedicated page for SMFR news (Ticker: SMFR), a resource for investors and traders seeking the latest updates and insights on SMFR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SMFR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SMFR's position in the market.
Sema4 (Nasdaq: SMFR) has announced the acquisition of OPKO Health's subsidiary, GeneDx, for approximately $623 million. The deal, expected to close in Q2 2022, aims to enhance Sema4's genomic testing capabilities and achieve a projected revenue of $350 million for 2022. The transaction includes a $200 million private placement led by Pfizer, strengthening Sema4's balance sheet. Katherine Stueland, former CEO of GeneDx, will join Sema4 as Co-CEO, alongside Eric Schadt. This merger is poised to transform patient care through advanced genomic solutions.
Sema4 (Nasdaq: SMFR) announced that fourth quarter and fiscal year 2021 results are expected to surpass previous guidance for both total revenue and test volume.
Projected fourth quarter revenues are forecasted at $50-52 million, exceeding earlier estimates of $46.6-49.6 million. Excluding COVID-19, the test volume should exceed 80,000 tests, compared to a guidance of 73,000-79,000.
For fiscal year 2021, total revenues are anticipated to top $201-204 million, reflecting at least 19% growth.
Sema4 (Nasdaq: SMFR) announced that CEO Eric Schadt and CFO Isaac Ro will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 4:30 p.m. ET. The event will be held virtually, with a live and archived audio-only webcast accessible on Sema4's investor relations website. Sema4 is an AI-driven genomic and clinical data intelligence platform focused on advancing healthcare through data insights. The company aims to transform healthcare using AI and machine learning to optimize individualized health trajectories.
Sema4 Holdings Corp. reported a strong third quarter for 2021, achieving a 36% increase in diagnostic test volumes and a 17% rise in revenue, totaling $43.2 million. The company anticipates total revenue for the full year to reach between $201 million and $204 million. Key highlights include significant growth in Oncology and Women’s Health sectors, increased lab capacity, and the launch of Sema4 Elements™. However, operating expenses surged to $74 million, reflecting investments in infrastructure and personnel. Net income reached $31.4 million.
Sema4 (NASDAQ: SMFR) recently published two studies showcasing the effectiveness of machine learning in predicting outcomes for postpartum hemorrhage (PPH). Conducted with Mount Sinai Health System, these studies leverage large-scale EMR data from over 70,000 deliveries, achieving an impressive 89% accuracy in PPH identification compared to 67% using standard methods. This novel predictive model incorporates 24 markers, including five new risk factors, potentially improving maternal health outcomes by enabling better risk assessment and resource allocation. The studies contribute significantly to the understanding of PPH's clinical management.
Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform, announced participation in three upcoming virtual investor conferences. Key events include the Stifel 2021 Virtual Healthcare Conference on November 16 at 2:40 p.m. ET, a Canaccord Genuity forum on November 18 at 11:30 a.m. ET, and the Jefferies London Healthcare Conference featuring 1x1 meetings on November 19. Live and archived webcasts will be available on the Sema4 investor relations website, enhancing investor engagement and information access.
Sema4 (SMFR), an AI-driven genomic and clinical data intelligence firm, announced it will release its Q3 2021 financial results on November 15, 2021, after market close. Following the results, CEO Eric Schadt and CFO Isaac Ro will host a conference call at 4:30 p.m. ET to discuss financial and operational performance. The event can be accessed via phone or live webcast on the company’s investor relations website. Sema4 aims to enhance healthcare through data-driven insights and its Centrellis® health intelligence platform.
Sema4 announced the appointment of Gustavo Stolovitzky as the new Chief Science Officer (CSO), a position aimed at enhancing the company's research and product development.
Dr. Stolovitzky, with over 25 years in the field, has a strong background in computational biology and high-throughput data analysis, previously serving at IBM Research.
His role will focus on advancing Sema4's AI-driven genomic platform and strengthening partnerships with health systems and the biopharmaceutical industry.
Sema4 has launched Sema4 Elements™, a new portfolio of genomic solutions aimed at enhancing reproductive and generational health. This includes advanced offerings like the Enhanced Carrier Screen (ECS) and Noninvasive Prenatal Testing (NIPT), providing personalized risk assessments based on genomic data. The ECS can identify up to 502 genetic conditions, significantly increasing the detection of high-risk pregnancies. Sema4 continues to leverage its Centrellis® platform for research and supports providers with customized workflows and genetic counseling.
Sema4 (Nasdaq: SMFR) announced participation in two upcoming virtual investor conferences. Eric Schadt, CEO, and Isaac Ro, CFO, will engage in fireside chats on September 10 at 8:40 a.m. ET during the Wells Fargo Securities Healthcare Conference and on September 13 at 9:30 a.m. ET at the Morgan Stanley 19th Annual Global Healthcare Conference. Live and recorded webcasts will be accessible through Sema4's investor relations website.
Sema4 focuses on patient-centered health intelligence, leveraging AI to enhance healthcare through comprehensive data analysis.
FAQ
What is the market cap of SMFR (SMFR)?
